The lung cancer genomic testing market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031.
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
Global Minimally Invasive Surgical Systems Market.pdfBIS Research Inc.
The global minimally invasive surgical systems market is estimated to be valued at $27,882.8 million in 2020 and is anticipated to reach $55,716.7 million by the end of 2031, growing at a CAGR of 6.3% during 2021-2031
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031.
Table of Content - U.S. Prostate Cancer Testing Market.pdfBIS Research Inc.
The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030.
Pharmaceutical Aseptic Transfer Market Analysis and Forecast, 2022-2031BIS Research Inc.
The global pharmaceutical aseptic transfer market is projected to reach $2,551.5 million by 2031 from $855.2 million in 2021 at a CAGR of 9.61% during the forecast period 2022-2031.
The Global Point-of-Care Imaging Devices Market was valued to be $8.66 billion in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $19.84 billion by 2030.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The global axial spondyloarthritis market was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032.
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
Global Minimally Invasive Surgical Systems Market.pdfBIS Research Inc.
The global minimally invasive surgical systems market is estimated to be valued at $27,882.8 million in 2020 and is anticipated to reach $55,716.7 million by the end of 2031, growing at a CAGR of 6.3% during 2021-2031
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031.
Table of Content - U.S. Prostate Cancer Testing Market.pdfBIS Research Inc.
The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030.
Pharmaceutical Aseptic Transfer Market Analysis and Forecast, 2022-2031BIS Research Inc.
The global pharmaceutical aseptic transfer market is projected to reach $2,551.5 million by 2031 from $855.2 million in 2021 at a CAGR of 9.61% during the forecast period 2022-2031.
The Global Point-of-Care Imaging Devices Market was valued to be $8.66 billion in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $19.84 billion by 2030.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The global axial spondyloarthritis market was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032.
Flow Cytometry in Oncology and Immunology Market Analysis and Forecast, 2022-...BIS Research Inc.
The global flow cytometry in oncology and immunology market is anticipated to reach $5,287.4 million by 2032, witnessing a CAGR of 11.39% during the forecast period 2022-2032.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
Our healthcare experts have found COVID-19 Diagnostic Testing industry to be one of the most rapidly evolving and dynamic markets and the global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021.
The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.
The global healthcare service robots market was valued to be $462.3 million in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $2.82 billion by 2025.
The global brain imaging modalities market report highlights that the market was valued at $12,334.2 million in 2021 and is expected to reach $20,209.2 million by the end of 2031. The market is expected to grow at a CAGR of 5.06% during the forecast period 2022-2031.
The global female technology market was estimated at $560.5 million in 2018 and is expected to witness a sharp growth of 17.18% during the forecast period 2019-2030.
DNA Methylation Market _ Industry Analysis & Report BIS Research Inc.
The current DNA methylation market is mainly dominated by several diagnostic majors, such as Exact Sciences Corporation, Illumina, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., which offer a wide variety of diagnostics and research-based products for detection of DNA methylation in genomes.
Contrast Media Agent and Injector System Market.pdfMohit BISResearch
Contrast media agent and injector system market is expected to reach $9,712 million by 2026, Contrast media agent and injector system industry at a CAGR of 6.20% between the period 2022-2026.
Read Report Overview: https://bisresearch.com/industry-report/contrast-media-agent-injector-system-market.html
The purpose of the study is to gain a holistic view of the active plasma medicine projects implemented in several countries. The report contains the analysis of various such as recent trends, technological advancements, reimbursement scenario, and international level initiatives across the globe influencing the adoption of plasma medicine.
Report Link- https://www.cognitivemarketresearch.com/Medical-Monitor-Market-Report Cognitive Market Research provides detailed analysis of Medical Monitor in our recently published report titled, "Medical Monitor 2022" The market study focuses on industry dynamics including driving factors to provide the key elements fueling the current market growth. The report also identifies restraints and opportunities to identify high growth segments involved in the Medical Monitor market. Key industrial factors such as macroeconomic and microeconomic factors are studied in detail with help of PESTEL analysis in order to have a holistic view of factors impacting Medical Monitor market growth across the globe. Market growth is forecasted with the help of complex algorithms such as regression analysis, sentiment analysis of end-users, etc. #MedicalMonitorReport #MedicalMonitorMarket #MedicalMonitorMarketForecast #MedicalMonitorMarketStatus #MedicalMonitorMarket2022
The global TOPCon solar cells market is anticipated to reach $40.69 billion by 2032, witnessing a CAGR of 19.8% during the forecast period 2023-2032.
Read Report Overview: https://bisresearch.com/industry-report/topcon-solar-cells-market.html
2D Materials Market growing at a CAGR of 25.3% during the forecast period 2022-2031. 2D materials report is published by bis research focus on end user, material type, and region.
Read Report Overview: https://bisresearch.com/industry-report/2d-materials-market.html
Castor Oil-Based Biopolymer Market is projected to reach $3,320.9 million by 2031. Castor Oil-Based Biopolymer Industry growing at a CAGR of 16.7% during the forecast period 2022-2031.
Read Report Overview: https://bisresearch.com/industry-report/castor-oil-based-biopolymer-market.html
The market size is expected to reach $12.9 Billion in 2030, from $ 2.58 Billion in 2019. The global liquid biopsy market is expected to grow at a robust rate of 15.87% during the forecast period, 2020-2030.
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.
Global Next Generation Oncology Devices and Solutions Market.pdfBIS Research Inc.
The global next-generation oncology devices and solutions market report highlights that the market was valued at $3,268.2 million in 2021 and is expected to reach $5,971.3 million by the end of 2031. The market is expected to grow at a CAGR of 6.41% during the forecast period from 2022 to 2031.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
Flow Cytometry in Oncology and Immunology Market Analysis and Forecast, 2022-...BIS Research Inc.
The global flow cytometry in oncology and immunology market is anticipated to reach $5,287.4 million by 2032, witnessing a CAGR of 11.39% during the forecast period 2022-2032.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
Our healthcare experts have found COVID-19 Diagnostic Testing industry to be one of the most rapidly evolving and dynamic markets and the global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021.
The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.
The global healthcare service robots market was valued to be $462.3 million in 2019 and is anticipated to witness an impressive double-digit growth rate, to reach $2.82 billion by 2025.
The global brain imaging modalities market report highlights that the market was valued at $12,334.2 million in 2021 and is expected to reach $20,209.2 million by the end of 2031. The market is expected to grow at a CAGR of 5.06% during the forecast period 2022-2031.
The global female technology market was estimated at $560.5 million in 2018 and is expected to witness a sharp growth of 17.18% during the forecast period 2019-2030.
DNA Methylation Market _ Industry Analysis & Report BIS Research Inc.
The current DNA methylation market is mainly dominated by several diagnostic majors, such as Exact Sciences Corporation, Illumina, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., which offer a wide variety of diagnostics and research-based products for detection of DNA methylation in genomes.
Contrast Media Agent and Injector System Market.pdfMohit BISResearch
Contrast media agent and injector system market is expected to reach $9,712 million by 2026, Contrast media agent and injector system industry at a CAGR of 6.20% between the period 2022-2026.
Read Report Overview: https://bisresearch.com/industry-report/contrast-media-agent-injector-system-market.html
The purpose of the study is to gain a holistic view of the active plasma medicine projects implemented in several countries. The report contains the analysis of various such as recent trends, technological advancements, reimbursement scenario, and international level initiatives across the globe influencing the adoption of plasma medicine.
Report Link- https://www.cognitivemarketresearch.com/Medical-Monitor-Market-Report Cognitive Market Research provides detailed analysis of Medical Monitor in our recently published report titled, "Medical Monitor 2022" The market study focuses on industry dynamics including driving factors to provide the key elements fueling the current market growth. The report also identifies restraints and opportunities to identify high growth segments involved in the Medical Monitor market. Key industrial factors such as macroeconomic and microeconomic factors are studied in detail with help of PESTEL analysis in order to have a holistic view of factors impacting Medical Monitor market growth across the globe. Market growth is forecasted with the help of complex algorithms such as regression analysis, sentiment analysis of end-users, etc. #MedicalMonitorReport #MedicalMonitorMarket #MedicalMonitorMarketForecast #MedicalMonitorMarketStatus #MedicalMonitorMarket2022
The global TOPCon solar cells market is anticipated to reach $40.69 billion by 2032, witnessing a CAGR of 19.8% during the forecast period 2023-2032.
Read Report Overview: https://bisresearch.com/industry-report/topcon-solar-cells-market.html
2D Materials Market growing at a CAGR of 25.3% during the forecast period 2022-2031. 2D materials report is published by bis research focus on end user, material type, and region.
Read Report Overview: https://bisresearch.com/industry-report/2d-materials-market.html
Castor Oil-Based Biopolymer Market is projected to reach $3,320.9 million by 2031. Castor Oil-Based Biopolymer Industry growing at a CAGR of 16.7% during the forecast period 2022-2031.
Read Report Overview: https://bisresearch.com/industry-report/castor-oil-based-biopolymer-market.html
The market size is expected to reach $12.9 Billion in 2030, from $ 2.58 Billion in 2019. The global liquid biopsy market is expected to grow at a robust rate of 15.87% during the forecast period, 2020-2030.
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.
Global Next Generation Oncology Devices and Solutions Market.pdfBIS Research Inc.
The global next-generation oncology devices and solutions market report highlights that the market was valued at $3,268.2 million in 2021 and is expected to reach $5,971.3 million by the end of 2031. The market is expected to grow at a CAGR of 6.41% during the forecast period from 2022 to 2031.
Similar to Lung Cancer Genomic Testing Market.pdf (20)
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
Cybersecurity in Automotive Connected Vehicles and Growing Security Vulnerabi...BIS Research Inc.
• Agenda:
o To evaluate various security vulnerabilities in connected vehicles.
o To analyze the initiatives taken and regulations implemented to address security vulnerabilities.
o To analyze the various types of cybersecurity solutions being developed or offered for the security of connected vehicles.
o To evaluate the major players in the ecosystem.
Report Preview is available at: https://bisresearch.com/industry-report/global-automotive-cybersecurity-market.html
BIS Research conducted a webinar on Carbon Neutral Data Center PracticesBIS Research Inc.
Agenda:
To evaluate various emerging trends in Data center industry.
To analyze the initiatives taken and regulations implemented to increase sustainable practices.
To analyze the various types of technologies currently deployed.
To evaluate the major players in the ecosystem.
Speaker Profiles:
Name: JD Enright, Sr.
Designation: Chief Operating Officer
Company: TMGcore Inc.
Experienced and dedicated business professional with 29 years working with DOD, Multinational Private and Public sector organizations. Primary focus on developing and executing Strategic Step-Up Growth initiatives in Emerging Markets, and Technologies. Specialized leadership in developing improved business operations to include Financial and Operational efficiencies. Implementation of next generation HPC Platforms, Global Blockchain Development Strategies, Biotechnology, Viral Cell and Gene Therapies and Market Intelligence Assimilation for public applications.
Webinar by BIS Research on Precision Oncology BiomarkersBIS Research Inc.
Precision oncology biomarkers are essential tools for tailoring cancer treatment to individual patients, as they provide insights into tumor biology and guide the selection of targeted therapies.
BIS conducted a deep intelligence webinar on the state-of-the-art technologies and emerging strategies used through the precision oncology biomarkers.
Direct-to-Customer Wellness | A Webinar on the Growing Need for Personalized ...BIS Research Inc.
Direct-to-consumer (DTC) wellness testing industry witnessed a strong emphasis on consumer health and wellness, instigating industry stakeholders to discover new revenue streams.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging trends in the healthcare sector, among several other industry verticals. In the bid to do the same, BIS is conducting a deep intelligence webinar on the increasing focus of DTC wellness programs in the healthcare sector.
Read Related Reports Overview at:
https://bisresearch.com/industry-report/global-direct-to-consumer-genetic-testing-market.html
https://bisresearch.com/industry-report/us-dtc-wellness-testing-market.html
Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Bat...BIS Research Inc.
The efficiency of the battery system in any electric vehicle (EV) determines its cost and vehicle performance. Challenges, such as range anxiety and charging time, have been a hindrance to increasing EV sales.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging technologies in the mobility sector, among several other industry verticals.
In the bid to do the same, BIS is conducting a deep intelligence webinar on the current paradigm shift happening for battery technologies in electric vehicles.
Here are all the details:
Webinar Topic: Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Batteries
Webinar on AI in Medical Diagnosis with Emerging TechnologiesBIS Research Inc.
Artificial Intelligence (AI) is a rapidly growing field that has the potential to revolutionize the way medical diagnosis is performed. AI systems use advanced algorithms to analyze large amounts of data, such as medical images, patient histories, and lab results, to identify patterns and make predictions about patient outcomes.
In medical diagnosis, AI can be used in a variety of ways, including medical imaging, disease diagnosis, personalized treatment planning, and early disease detection. By leveraging the power of AI, healthcare providers can make faster and more accurate diagnoses, resulting in better patient outcomes.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Policy implications related to AI and digital transformation in healthcare.
• Initiatives taken and regulations implemented to address cybersecurity concerns.
• Major factors driving and hindering the growth of AI in medical devices diagnosis.
• Major players in the ecosystem
The global demand for achieving the net zero emission target by 2050 has pushed governments all over to adapt and adopt advanced carbon removal technologies to go carbon negative.
It is, indeed, an important topic of discussion, because a carbon free environment is the need of the hour to save our planet. And, therefore, BIS Research is glad to announce its upcoming webinar on this particular subject.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Primary sources of carbon emissions and associated environmental issues
• Carbon dioxide removal – key technology and adoption scenario
• Carbon dioxide removal (CDR): trends and key market developments
• Carbon dioxide removal as a credible solution
• Conclusion and future outlook
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
Agenda of the Webinar:
Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
Awaited Technologies in the Cell and Gene Therapy Development
Regulatory Scenario – GMP/cGMP Guidelines
Biomanufacturing 4.0 - Adoption Scenario
Conclusion and Future Outlook
Sub-Orbital Testing Services Market Future Growth and Business Opportunities ...BIS Research Inc.
Sub-orbital platforms are increasing access to the near space-like environment for end users such as government agencies, research institutions, and commercial players.
The competitive landscape of the sub-orbital testing services market consists of several organic and inorganic strategies followed by the key players to increase their market share.
The space industry is continuously innovating and developing advanced technologies with the objective of enhancing space capabilities. The industry is gearing up to develop vehicles that entail a major feature, i.e., reusability.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
TOC - Global Military Robotic and Autonomous Systems (RAS) Market.pdfBIS Research Inc.
The robotic and autonomous system (RAS) is a multidisciplinary scientific and technological domain for implementing complex systems with cognitive capabilities.
RAS in military is being rigorously introduced and used in combat training. This has boosted the capabilities of armed units and subunits. The advent of artificial intelligence (AI) and its integration with military RAS has the potential to change future warfare.
Growing demand to increase warfighter lethality and remove soldiers from dangerous situations is propelling the global military RAS market.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
UAV Propulsion System Market Analysis, Statistics, Regional, and Forecast to ...BIS Research Inc.
UAV propulsion system manufacturers have also been inclined to counter the environment and other government regulations by developing sustainable propulsion, i.e., steps toward fossil-free aviation fuels and ion propulsion are a few of such significant innovations.
UAVs can be powered by a variety of different types of engines, including piston engines, turbine engines, Wankel engines, and electric and solar-powered engines.
The global UAV propulsion system market has witnessed a high growth rate in the last five to six years owing to its widespread applications across various industries, which were further bolstered by the COVID-19 pandemic.
Publication of BIS Research on UAV Propulsion System market has some great insights for UAV Propulsion Systems. Get free sample here: https://bisresearch.com/requestsample?id=1443&type=download
Fleet Management Market Trends, Key Players, Industry Analysis and Forecast 2...BIS Research Inc.
A fleet management system, which includes hardware, software and service, has the ability to make decisions for fleet managers and fleet businesses easily.
The ongoing research and development activities in this market are experiencing product launches of fleet management system for fleet owners, fleet managers, or businesses that utilize fleet management on a daily basis.
BIS Research has a new publication on Fleet Management, view free sample here : https://bisresearch.com/requestsample?id=1444&type=download
Agenda:
The main agenda of this webinar is to understand and explore the following:
• LoRaWAN adoption in agricultural applications as well as understanding the trends and key market developments.
• The significance of LoRaWAN in the field of IoT
• A comparative analysis between LoRaWAN and other IoT networks in terms of technology and capabilities.
• The impact of LoRaWAN on the operations of the agriculture industry and common use cases.
• The impact of the implementation of LoRaWAN technology on stakeholders in the agriculture ecosystem.
• The potential challenges that LoRaWAN might face in the future.
• The competitiveness of the market for LoRaWAN technology.
Augmented Reality in Agriculture Analysis and Statistics from 2022-2027BIS Research Inc.
AR depicts superimposing visual, audio, or other sensory data onto the physical world to improve one's experience. It is one of the most popular technological trends in today’s times. AR images can be displayed on a variety of devices, including eyeglasses and goggles, headsets, and heads-up displays such as helmet visors. As more smartphones, tablets, and other handheld devices that support AR are becoming available globally, the most popular way to use AR is on these devices in a variety of apps and games.
Although AR is used to visually communicate information, it is the integration of AR with other technologies that make it possible to adapt to precision farming and visual-based operations. Hence, farmers can utilize AR in combination with other technologies such as artificial intelligence (AI), big data, and the Internet of Things (IoT) to manage the rising food demand.
Get Augmented Reality in Agriculture report overview at: https://bisresearch.com/industry-report/ar-agriculture-market.html
Smart Harvest Market Generated Opportunities, Future Scope 2022-2027BIS Research Inc.
The growth in the global smart harvest market is expected to be driven by increasing smart farming practices among farmers, labor shortage, and growing government support for promoting the use of smart tech in the agriculture industry. Supported by government policies and technological developments, farmers and growers across the globe are expected to increase the implementation of smart harvest technologies. Moreover, the smart harvest market is witnessing several upcoming trends and opportunities, further propelling growth in the industry.
Get the PDF document on the technical aspects of Smart Harvest Market at: https://bisresearch.com/requestsample?id=1386&type=download
Precision Pest Management Market Leading Players, Development and Demand Fore...BIS Research Inc.
While farmers are losing crops due to pests, they have pressure to increase food production to feed the growing world population.
Precision pest management (PPM) is very important to avoid destruction caused by pests and to increase productivity. PPM helps to detect pests early with the help of crop monitoring so they can be controlled early to avoid further losses. The availability of advanced technologies and equipment has made agriculture automation more prevalent in developed countries.
To know more about the in-depth insights on precision pest management market, get PDF document: https://bisresearch.com/requestsample?id=1404&type=download
Agriculture Drones and Robots Market Growth Opportunity, Trends, Demand Analy...BIS Research Inc.
Agriculture drones and robots offer multiple benefits over conventional farming equipment, which is another factor driving the demand for these products in the agriculture industry. The adoption of agriculture drones and robots in commercial farms offers huge cost-saving opportunities.
Request for the Sample of the Report at: https://bisresearch.com/requestsample?id=1425&type=download
Next-Generation Automotive Lighting Industry to See Significant Growth During...BIS Research Inc.
Since the inception of automotive vehicles amongst the masses, automotive lighting has witnessed significant growth owing to the growing safety apprehensions revolving around vehicles.
The rapid technical progress in the automotive lighting field shows that basic light sources based on incandescent and gas-release bulbs have shifted to modern-day technologies such as light-emitting diodes (LEDs), laser technology, and organic light-emitting diodes (OLEDs).
Get the Sample of the Report containing the information on various technical aspects at: https://bisresearch.com/requestsample?id=1435&type=download
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
Lung Cancer Genomic Testing Market.pdf
1. 1
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
https://www.freepik.com/premium-photo/close-up-view-96-well-plate-used-biology-
research_2652534.htm#page=1&query=96%20well%20plate&position=21&from_view=keyword
Focus on Product, Technology, Panel
Type, Sample Type, and End User
Analysis and Forecast: 2021-2031
May 2022
Lung Cancer
Genomic Testing
Market -
A Global and
Regional Analysis
Table of Content
3. 3
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
Table of Content
Executive Summary..........................................................................25
1. Markets .....................................................................................33
1.1 Product Definition............................................................................................34
1.1.1 Lung Cancer Genomic Testing...................................................................34
1.1.2 Inclusion and Exclusion .............................................................................34
1.1.3 Market Scope ...............................................................................................34
1.1.3.1 Key Questions Answered by this Report: .......................................................... 35
1.2 Research Methodology ...................................................................................36
1.2.1 Primary Data Sources .................................................................................37
1.2.2 Secondary Data Sources ............................................................................38
1.3 Market Estimation Model.................................................................................39
1.4 Criteria for Company Profiling........................................................................41
2. Market Overview........................................................................42
2.1 Introduction......................................................................................................43
2.2 Global Prevalence of Lung Cancer ................................................................44
2.3 Significance of Genomic Testing in Lung Cancer ........................................45
2.4 COVID-19 Impact on Lung Cancer Genomic Testing Market.......................46
2.4.1 Disruption in Global Lung Cancer Genomic Testing Market: Pre-
and Post-COVID-19 Market Analysis .........................................................46
2.4.2 COVID-19 Affecting Supply Chain of Global Lung Cancer Genomic
Testing Market .............................................................................................48
2.4.3 Interruption in Research and Clinical Development and Commercial
Operation .....................................................................................................49
2.4.4 Navigating Crisis Recovery and Looking to the Future...........................49
3. Industry Analysis .......................................................................51
3.1 Global Legal Requirements and Regulations................................................52
3.1.1 Legal Requirements and Frameworks in the U.S. ....................................52
3.1.1.1 Centers for Medicare & Medicaid Services Regulation ..................................... 54
3.1.2 Legal Requirements and Frameworks in Europe .....................................55
4. 4
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
3.1.3 Legal Requirements and Frameworks in Asia-Pacific .............................57
3.1.3.1 China ................................................................................................................. 57
3.1.3.2 Japan................................................................................................................. 57
3.1.4 Latin America (Brazil and Mexico) .............................................................59
3.2 Patent Landscape............................................................................................60
3.2.1 Patent Filing Trend......................................................................................60
3.2.2 Patent Analysis by Country........................................................................60
3.2.3 Patent Analysis by Technology..................................................................61
4. Market Dynamics .......................................................................62
4.1 Overview...........................................................................................................63
4.2 Impact Analysis ...............................................................................................63
4.3 Market Driving Factors....................................................................................64
4.3.1 High Lung Cancer Mortality Rate...............................................................64
4.3.2 Advancements in the Next-Generation Technologies for Genomic
Testing..........................................................................................................66
4.3.3 Increasing Number of Targeted Therapies................................................67
4.3.4 Decreasing Cost of Genetic Testing Globally...........................................68
4.4 Market Restraining Factors.............................................................................68
4.4.1 Uncertain Regulatory Scenario for Genomic Testing ..............................68
4.4.2 Lack of Viable Tissue Biopsy Sample .......................................................69
4.4.3 Uneven Reimbursement Scenario for Genomic Testing..........................69
4.5 Market Opportunities.......................................................................................70
4.5.1 Improving Global Recommendations for Lung Cancer Genomic
Testing..........................................................................................................70
4.5.1.1 American Society of Clinical Oncology (ASCO) Recommendations ................. 70
4.5.1.2 European Society of Clinical Oncology (ESMO) Recommendations................. 71
4.5.1.3 Pan-Asia Clinical Practical Guidelines............................................................... 72
4.5.2 Rising Investment in Research and Development....................................72
4.5.3 Emerging Economies..................................................................................73
5. Competitive Landscape .............................................................74
5. 5
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
5.1 Key Strategies and Developments.................................................................75
5.1.1 Synergistic Activities ..................................................................................76
5.1.2 Regulatory Approvals .................................................................................78
5.1.3 Product Launches and Upgradations........................................................79
5.1.4 Mergers and Acquisitions...........................................................................80
5.1.5 Business Expansion ...................................................................................80
5.1.6 Investment, Funding, and Joint Venture ...................................................81
5.1.7 Market Share Analysis by Company..........................................................82
5.1.8 Growth-Share Analysis by Company.........................................................83
6. Global Lung Cancer Genomic Testing Market, (by Product
Type), $Million, 2020-2031 .........................................................85
6.1 Overview...........................................................................................................86
6.1.1 Products.......................................................................................................87
6.1.2 Services........................................................................................................88
7. Global Lung Cancer Genomic Testing Market, (by
Technology), $Million, 2020-2031...............................................90
7.1 Overview...........................................................................................................91
7.2 Next-Generation Sequencing..........................................................................91
7.3 Polymerase Chain Reaction (PCR).................................................................93
7.4 Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)........94
7.5 Others ...............................................................................................................95
8. Global Lung Cancer Genomic Testing Market, (by Panel Type),
$Million, 2020-2031....................................................................96
8.1 Overview...........................................................................................................97
8.2 Single-Gene......................................................................................................97
8.3 Multi-Gene Panel..............................................................................................98
9. Global Lung Cancer Genomic Testing Market, (by Sample
Type), $Million, 2020-2031 .......................................................100
9.1 Overview.........................................................................................................101
9.2 Tissue Biopsy ................................................................................................101
6. 6
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
9.3 Liquid Biopsy.................................................................................................102
9.3.1 cfDNA .........................................................................................................104
9.3.2 ctDNA .........................................................................................................105
10. Global Lung Cancer Genomic Testing Market, (by End User),
$Million, 2020-2031..................................................................106
10.1 Overview.........................................................................................................107
10.2 Research Organization..................................................................................108
10.3 Hospitals/Clinics............................................................................................109
10.4 Diagnostic Laboratories................................................................................110
10.5 Other End Users ............................................................................................111
11. Global Lung Cancer Genomic Testing Market (by Region),
$Million, 2020-2031..................................................................112
11.1 Overview.........................................................................................................113
11.2 North America................................................................................................115
11.2.1 North America: Market Dynamics ............................................................116
11.2.2 North America: Key Trends ......................................................................117
11.2.3 U.S. .............................................................................................................117
11.2.4 Canada .......................................................................................................119
11.3 Latin America.................................................................................................121
11.3.1 Brazil...........................................................................................................123
11.3.2 Mexico ........................................................................................................124
11.3.3 Rest-of-Latin America (RoLA) ..................................................................124
11.4 Europe ............................................................................................................127
11.4.1 Europe: Market Dynamics ........................................................................129
11.4.2 Europe: Key Trends ..................................................................................130
11.4.3 U.K. .............................................................................................................130
11.4.4 Germany.....................................................................................................131
11.4.5 Italy .............................................................................................................132
11.4.6 Spain...........................................................................................................133
11.4.7 France.........................................................................................................134
7. 7
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
11.4.8 Rest-of-Europe...........................................................................................134
11.5 Asia-Pacific ....................................................................................................137
11.5.1 Asia-Pacific Lung Cancer Genomic Testing: Market Dynamics............137
11.5.2 Asia-Pacific: Key Trends ..........................................................................139
11.5.3 Japan..........................................................................................................139
11.5.4 China ..........................................................................................................140
11.5.5 South-Korea...............................................................................................141
11.5.6 Singapore...................................................................................................142
11.5.7 Australia.....................................................................................................143
11.5.8 India............................................................................................................144
11.5.9 Rest-of-Asia-Pacific...................................................................................144
11.6 Rest-of-the-World ..........................................................................................146
11.6.1 Key Trends in Rest-of-the-World Lung Cancer Genomic Testing
Market.........................................................................................................147
12. Company Profiles.....................................................................148
12.1 Overview.........................................................................................................149
12.2 QIAGEN N.V....................................................................................................150
12.2.1 Company Overview ...................................................................................150
12.2.2 Role of QIAGEN N.V. in the Global Lung Cancer Genomic Testing
Market.........................................................................................................150
12.2.3 Key Competitors........................................................................................151
12.2.4 Key Customers ..........................................................................................151
12.2.5 Financials...................................................................................................151
12.2.5.1 Key Insights About Financial Health of the Company...................................... 153
12.2.6 Corporate Strategies.................................................................................153
12.2.6.1 Mergers and Acquisitions ................................................................................ 153
12.2.6.2 Synergistic Activities........................................................................................ 154
12.2.6.3 Business Expansion and Funding ................................................................... 154
12.2.6.4 Product Launches and Upgradation ................................................................ 154
12.2.7 SWOT Analysis..........................................................................................155
8. 8
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.3 Agilent Technologies, Inc. ............................................................................156
12.3.1 Company Overview ...................................................................................156
12.3.2 Role of Agilent Technologies, Inc. in the Global Lung Cancer
Genomic Testing Market...........................................................................156
12.3.3 Key Competitors........................................................................................157
12.3.4 Key Customers ..........................................................................................157
12.3.5 Financials...................................................................................................157
12.3.5.1 Key Insights About Financial Health of the Company...................................... 159
12.3.6 Corporate Strategies.................................................................................160
12.3.6.1 Mergers and Acquisitions ................................................................................ 160
12.3.6.2 Synergistic Activities........................................................................................ 160
12.3.6.3 Business Expansion and Funding ................................................................... 160
12.3.6.4 Product Launches and Upgradation ................................................................ 160
12.3.7 SWOT Analysis..........................................................................................161
12.4 Thermo Fisher Scientific, Inc........................................................................162
12.4.1 Company Overview ...................................................................................162
12.4.2 Role of Thermo Fisher Scientific, Inc. in the Global Lung Cancer
Genomic Testing Market...........................................................................162
12.4.3 Key Competitors........................................................................................163
12.4.4 Key Customers ..........................................................................................163
12.4.5 Financials...................................................................................................164
12.4.5.1 Key Insights About Financial Health of the Company...................................... 166
12.4.6 Corporate Strategies.................................................................................166
12.4.6.1 Mergers and Acquisitions ................................................................................ 166
12.4.6.2 Synergistic Activities........................................................................................ 166
12.4.6.3 Business Expansion and Funding ................................................................... 167
12.4.6.4 Product Launches and Upgradation ................................................................ 167
12.4.7 SWOT Analysis..........................................................................................168
12.5 Quest Diagnostics Incorporated ..................................................................169
12.5.1 Company Overview ...................................................................................169
9. 9
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.5.2 Role of Quest Diagnostics Incorporated in the Global Lung Cancer
Genomic Testing Market...........................................................................169
12.5.3 Key Competitors........................................................................................170
12.5.4 Key Customers ..........................................................................................170
12.5.5 Financials...................................................................................................170
12.5.6 Corporate Strategies.................................................................................172
12.5.6.1 Mergers and Acquisitions ................................................................................ 172
12.5.6.2 Synergistic Activities........................................................................................ 172
12.5.6.3 Business Expansion and Funding ................................................................... 172
12.5.6.4 Product Launches and Upgradation ................................................................ 172
12.5.7 SWOT Analysis..........................................................................................173
12.6 Laboratory Corporation of America Holdings.............................................174
12.6.1 Company Overview ...................................................................................174
12.6.2 Role of Laboratory Corporation of America Holdings in the Global
Lung Cancer Genomic Testing Market....................................................174
12.6.3 Key Competitors........................................................................................175
12.6.4 Key Customers ..........................................................................................175
12.6.5 Financials...................................................................................................176
12.6.6 Corporate Strategies.................................................................................177
12.6.6.1 Mergers and Acquisitions ................................................................................ 177
12.6.6.2 Synergistic Activities........................................................................................ 178
12.6.6.3 Business Expansion and Funding ................................................................... 178
12.6.6.4 Product Launches and Upgradation ................................................................ 178
12.6.7 SWOT Analysis..........................................................................................179
12.7 CENTOGENE N.V...........................................................................................180
12.7.1 Company Overview ...................................................................................180
12.7.2 Role of CENTOGENE N.V. in the Global Lung Cancer Genomic
Testing Market ...........................................................................................180
12.7.3 Key Competitors........................................................................................181
12.7.4 Key Customers ..........................................................................................181
12.7.5 Financials...................................................................................................181
10. 10
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.7.6 Key Insights About Financial Health of the Company ...........................183
12.7.7 Corporate Strategies.................................................................................183
12.7.7.1 Mergers and Acquisitions ................................................................................ 183
12.7.7.2 Synergistic Activities........................................................................................ 183
12.7.7.3 Business Expansion and Funding ................................................................... 183
12.7.7.4 Product Launches and Upgradation ................................................................ 184
12.7.8 SWOT Analysis..........................................................................................184
12.8 BGI ..................................................................................................................185
12.8.1 Company Overview ...................................................................................185
12.8.2 Role of BGI in the Global Lung Cancer Genomic Testing Market.........185
12.8.3 Key Competitors........................................................................................186
12.8.4 Key Customers ..........................................................................................186
12.8.5 Corporate Strategies.................................................................................186
12.8.5.1 Mergers and Acquisitions ................................................................................ 186
12.8.5.2 Synergistic Activities........................................................................................ 186
12.8.5.3 Business Expansion and Funding ................................................................... 186
12.8.5.4 Product Launches and Upgradation ................................................................ 186
12.8.6 SWOT Analysis..........................................................................................187
12.9 CeGaT GmbH .................................................................................................188
12.9.1 Company Overview ...................................................................................188
12.9.2 Role of CeGaT GmbH in the Global Lung Cancer Genomic Testing
Market.........................................................................................................188
12.9.3 Key Competitors........................................................................................189
12.9.4 Key Customers ..........................................................................................189
12.9.5 Corporate Strategies.................................................................................189
12.9.5.1 Mergers and Acquisitions ................................................................................ 189
12.9.5.2 Synergistic Activities........................................................................................ 189
12.9.5.3 Business Expansion and Funding ................................................................... 189
12.9.5.4 Product Launches and Upgradation ................................................................ 190
12.9.6 SWOT Analysis..........................................................................................190
11. 11
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.10 Illumina, Inc....................................................................................................191
12.10.1 Company Overview............................................................................191
12.10.2 Role of Illumina, Inc. in the Global Lung Cancer Genomic
Market.........................................................................................................191
12.10.3 Key Competitors ................................................................................193
12.10.4 Key Customers...................................................................................193
12.10.5 Financials ...........................................................................................193
12.10.5.1 Key Insights About Financial Health of the Company..................................... 195
12.10.6 Corporate Strategies..........................................................................196
12.10.6.1 Mergers and Acquisitions ............................................................................... 196
12.10.6.2 Synergistic Activities....................................................................................... 196
12.10.6.3 Business Expansion and Funding .................................................................. 196
12.10.6.4 Product Launches and Upgradation ............................................................... 196
12.10.7 SWOT Analysis...................................................................................197
12.11 F. Hoffmann-La Roche Ltd............................................................................198
12.11.1 Company Overview............................................................................198
12.11.2 Role of F. Hoffmann-La Roche Ltd. in the Global Lung Cancer
Genomic Testing Market...........................................................................198
12.11.3 Key Competitors ................................................................................199
12.11.4 Key Customers...................................................................................199
12.11.5 Financials ...........................................................................................200
12.11.6 Key Insights About Financial Health of the Company ....................202
12.11.7 Corporate Strategies..........................................................................202
12.11.7.1 Mergers and Acquisitions ............................................................................... 202
12.11.7.2 Synergistic Activities....................................................................................... 203
12.11.7.3 Business Expansion and Funding .................................................................. 203
12.11.7.4 Product Launches and Upgradation ............................................................... 203
12.11.8 SWOT Analysis...................................................................................204
12.12 Abbott Laboratories ......................................................................................205
12.12.1 Company Overview............................................................................205
12. 12
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.12.2 Role of Abbott Laboratories in the Global Lung Genomic
Testing Market ...........................................................................................205
12.12.3 Key Competitors ................................................................................206
12.12.4 Key Customers...................................................................................206
12.12.5 Financials ...........................................................................................206
12.12.6 Key Insights About Financial Health of the Company ....................208
12.12.7 Corporate Strategies..........................................................................208
12.12.7.1 Mergers and Acquisitions ............................................................................... 208
12.12.7.2 Synergistic Activities....................................................................................... 208
12.12.7.3 Business Expansion and Funding .................................................................. 209
12.12.7.4 Product Launches and Upgradation ............................................................... 209
12.12.8 SWOT Analysis...................................................................................209
12.13 CD Genomics .................................................................................................210
12.13.1 Company Overview............................................................................210
12.13.2 Role of CD Genomics in the Global Lung Cancer Genomic
Testing Market ...........................................................................................210
12.13.3 Key Competitors ................................................................................211
12.13.4 Key Customers...................................................................................211
12.13.5 Corporate Strategies..........................................................................212
12.13.5.1 Mergers and Acquisitions ............................................................................... 212
12.13.5.2 Synergistic Activities....................................................................................... 212
12.13.5.3 Business Expansion and Funding .................................................................. 212
12.13.5.4 Product Launches and Upgradation ............................................................... 212
12.13.6 SWOT Analysis...................................................................................213
12.14 NeoGenomics Laboratories..........................................................................214
12.14.1 Company Overview............................................................................214
12.14.2 Role of NeoGenomics Laboratories in the Global Lung Cancer
Genomic Testing Market...........................................................................214
12.14.3 Key Competitors ................................................................................215
12.14.4 Key Customers...................................................................................215
12.14.5 Financials ...........................................................................................216
13. 13
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.14.6 Key Developments.............................................................................216
12.14.7 Key Insights About Financial Health of the Company ....................217
12.14.8 Corporate Strategies..........................................................................218
12.14.8.1 Mergers and Acquisitions ............................................................................... 218
12.14.8.2 Synergistic Activities....................................................................................... 218
12.14.8.3 Business Expansion and Funding .................................................................. 218
12.14.8.4 Product Launches and Upgradation ............................................................... 218
12.14.9 SWOT Analysis...................................................................................219
12.15 Admera Health ...............................................................................................220
12.15.1 Company Overview............................................................................220
12.15.2 Role of Admera Health in the Global Lung Cancer Genomic
Testing Market ...........................................................................................220
12.15.3 Key Competitors ................................................................................221
12.15.4 Key Customers...................................................................................221
12.15.5 Corporate Strategies..........................................................................221
12.15.5.1 Mergers and Acquisitions ............................................................................... 221
12.15.5.2 Synergistic Activities....................................................................................... 221
12.15.5.3 Business Expansion and Funding .................................................................. 222
12.15.5.4 Product Launches and Upgradation ............................................................... 222
12.15.6 SWOT Analysis...................................................................................223
12.16 OncoDNA........................................................................................................224
12.16.1 Company Overview............................................................................224
12.16.2 Role of OncoDNA in the Global Lung Cancer Genomic Testing
Market.........................................................................................................224
12.16.3 Key Competitors ................................................................................225
12.16.4 Key Customers...................................................................................225
12.16.5 Corporate Strategies..........................................................................225
12.16.5.1 Mergers and Acquisitions ............................................................................... 225
12.16.5.2 Synergistic Activities....................................................................................... 225
12.16.5.3 Business Expansion and Funding .................................................................. 225
14. 14
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.16.5.4 Product Launches and Upgradation ............................................................... 226
12.16.6 SWOT Analysis...................................................................................226
12.17 OPKO Health, Inc...........................................................................................227
12.17.1 Company Overview............................................................................227
12.17.2 Role of OPKO Health, Inc. in the Global Lung Cancer Genomic
Testing Market ...........................................................................................227
12.17.3 Key Competitors ................................................................................228
12.17.4 Key Customers...................................................................................228
12.17.5 Financials ...........................................................................................228
12.17.6 Key Insights About Financial Health of the Company ....................230
12.17.7 Corporate Strategies..........................................................................230
12.17.7.1 Mergers and Acquisitions ............................................................................... 230
12.17.7.2 Synergistic Activities....................................................................................... 230
12.17.7.3 Business Expansion and Funding .................................................................. 230
12.17.7.4 Product Launches and Upgradation ............................................................... 230
12.17.8 SWOT Analysis...................................................................................231
12.18 Emerging Companies....................................................................................232
12.18.1 Invitae Corporation ............................................................................232
12.18.1.1 Company Overview ........................................................................................ 232
12.18.1.2 Role of Invitae Corporation in the Global Lung Cancer Genomic Testing
Market............................................................................................................. 232
12.18.1.3 Key Competitors ............................................................................................. 233
12.18.1.4 Key Customers ............................................................................................... 233
12.18.1.5 Financials........................................................................................................ 233
12.18.1.6 Key Insights About Financial Health of the Company..................................... 234
12.18.1.7 Corporate Strategies....................................................................................... 235
12.18.1.7.1 Mergers and Acquisitions...................................................................................... 235
12.18.1.7.2 Product Launches and Upgradation...................................................................... 235
12.18.1.8 SWOT Analysis............................................................................................... 236
12.18.2 Veracyte, Inc.......................................................................................237
15. 15
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
12.18.2.1 Company Overview ........................................................................................ 237
12.18.2.2 Role of Veracyte, Inc. in the Global Lung Cancer Genomic Testing
Market............................................................................................................. 237
12.18.2.3 Key Competitors ............................................................................................. 238
12.18.2.4 Key Customers ............................................................................................... 238
12.18.2.5 Financials........................................................................................................ 238
12.18.2.6 Key Insights About Financial Health of the Company..................................... 240
12.18.2.7 Corporate Strategies....................................................................................... 240
12.18.2.7.1 Mergers and Acquisitions...................................................................................... 240
12.18.2.7.2 Product Launches and Upgradation...................................................................... 241
12.18.2.8 SWOT Analysis............................................................................................... 241
16. 16
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
List of Figures
Figure 1: Types of Lung Cancer
Figure 2: Incidence and Mortality of Lung Cancer (in Thousands), 2018 and 2020
Figure 3: Global Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 4: Global Lung Cancer Genomic Testing Market, Market Dynamics
Figure 5: Share of Key Developments and Strategies, January 2017-February 2022
Figure 6: Global Lung Cancer Genomic Testing Market (by Product Type), $Million, 2020 vs. 2031
Figure 7: Global Lung Cancer Genomic Testing Market (by Technology), $Million, 2020 vs. 2031
Figure 8: Global Lung Cancer Genomic Testing Market (by Sample Type), $Million, 2020 vs. 2031
Figure 9: Global Lung Cancer Genomic Testing Market (by Panel Type), $Million, 2020 vs. 2031
Figure 10: Global Lung Cancer Genomic Testing Market (by End User), $Million, 2020 vs. 2031
Figure 11: Global Lung Cancer Genomic Testing Market (by Region), $Million, 2020 vs. 2031
Figure 12: Global Lung Cancer Genomic Testing Market: Segmentation
Figure 14: Primary Research Methodology
Figure 15: Bottom-Up Approach (Segment-Wise Analysis)
Figure 16: Top-Down Approach (Segment-Wise Analysis)
Figure 17: Global Five-Year Prevalence of Lung Cancer, 2015-2020 (in Thousands)
Figure 18: Global Lung Cancer Genomics Testing Market: COVID-19 Impact Analysis
Figure 19: COVID-19 Impact (March-June 2020)
Figure 20: Biomarker Testing Reduction in the U.S.: February-March 2020
Figure 21: Recommendations to Navigate COVID-19 Crisis
Figure 22: FDA Guidelines for Companion Diagnostics Approval
Figure 23: Criteria for CMS Coverage/Reimbursement
Figure 24: Components Considered for Clinical Actionability as per the In-Vitro Diagnostic Medical
Devices Regulation
Figure 25: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
Figure 26: China NMPA Regulatory Approval Process
Figure 27: Steps to Register a Medical Device in Japan
Figure 28: Regulatory Approval for Medical Devices in Latin-America
Figure 29: Country-Wise Analysis (January 2019-January 2022) of Patents Related to Lung Cancer
Genomic Testing
Figure 30: Technology Wise Analysis (January 2019-January 2022) of Patents Related to Lung Cancer
Genomic Testing
Figure 31: Market Dynamics
17. 17
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
Figure 32: Likert Scale
Figure 33: Impact Analysis
Figure 34: Global Cancer Incidence (2020)
Figure 35: Global Cancer Mortality (2020)
Figure 36: Estimated Lung Cancer New Cases and Death in the U.S. in 2030 (in Thousands)
Figure 37: Cost of Genome Sequencing (2014-2021)
Figure 38: In-Vitro Diagnostics and Laboratory Developed Test Regulatory in the U.S., Europe, and
Japan
Figure 39: Reimbursement Barriers in U.S., Europe, and APAC regions
Figure 40: ASCO Non-Small Cell Lung Cancer Biomarker Test Recommendations
Figure 41: ESMO Recommendations as per ESMO Scale for Clinical Actionability of Molecular Targets
(ESCAT) Level for NGS Panel Test
Figure 42: Pan-Asia NSCLC Clinical Recommendations
Figure 43: Number of Cancer Research Funders Globally
Figure 44: Share of Key Developments and Strategies, January 2017-February 2022
Figure 45: Synergistic Activities Share (by Company), January 2017-January 2022
Figure 46: Product and Regulatory Approvals (by Company), January 2017-January 2022
Figure 47: Product Launches and Upgradations (by Company), January 2017–February 2022
Figure 48: Share of Acquisitions (by Company), January 2017-February 2022
Figure 49: Share of Business Expansion (by Company), January 2017-February 2022
Figure 50: Market Share Analysis for Global Lung Cancer Genomics Testing Market, $Million, 2019 and
2020
Figure 51: Growth-Share Analysis of Global Lung Cancer Genomics Testing Market (by Company) 2019-
2020
Figure 52: Global Lung Cancer Genomic Testing Market (by Product Type)
Figure 53: Global Lung Cancer Genomic Testing Market (by Product Type), 2020 and 2031
Figure 54: Global Lung Cancer Genomic Testing Market (by Product Type), $Million, 2020-2031
Figure 55: Global Lung Cancer Genomic Testing Market (Services), $Million, 2020-2031
Figure 56: Global Lung Cancer Genomic Testing Market (Technology), 2020 and 2031
Figure 57: Global Lung Cancer Genomic Testing Market (Next-Generation Sequencing), $Million, 2020-
2031
Figure 58: Global Lung Cancer Genomic Testing Market (Polymerase Chain Reaction), $Million, 2020-
2031
Figure 59: Global Lung Cancer Genomic Testing Market (Fluorescence In-Situ Hybridization), $Million,
2020-2031
18. 18
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
Figure 60: Global Lung Cancer Genomic Testing Market (Other), $Million, 2020-2031
Figure 61: Global Lung Cancer Genomic Testing Market (by Panel Type), 2020 and 2031
Figure 62: Global Lung Cancer Genomic Testing Market (Single-Gene Panel Type), $Million, 2020-2031
Figure 63: Global Lung Cancer Genomic Testing Market (Multi-Gene Panel Type), $Million, 2020-2031
Figure 64: Global Lung Cancer Genomic Testing Market (by Sample Type), $Million, 2020 and 2031
Figure 65: Global Lung Cancer Genomic Testing Market (Tissue Biopsy), $Million, 2020-2031
Figure 66: Global Lung Cancer Genomic Testing Market (Liquid Biopsy), $Million, 2020-2031
Figure 67: Global Lung Cancer Genomic Testing Market (Liquid Biopsy), $Million, 2020-2031
Figure 68: Global Lung Cancer Genomic Testing Market (cfDNA), $Million, 2020-2031
Figure 69: Global Lung Cancer Genomic Testing Market (ctDNA), $Million, 2020-2031
Figure 71: Global Lung Cancer Genomic Testing Market (by End User), $Million, 2020 and 2031
Figure 72: Global Lung Cancer Genomic Testing Market (Research Organization), $Million, 2020-2031
Figure 73: Global Lung Cancer Genomic Testing Market (Hospitals/Clinics), $Million, 2020-2031
Figure 74: Global Lung Cancer Genomic Testing Market (Diagnostic Laboratories), $Million, 2020-2031
Figure 75: Global Lung Cancer Genomic Testing Market (Other End Users), $Million, 2020-2031
Figure 76: Market Share of North America Lung Cancer Genomic Testing Market Revenue (by Country),
$Million, 2020 and 2031
Figure 77: North America: Market Dynamics
Figure 78: North America: Key Trends
Figure 79: U.S. Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 80: Estimated Lung Cancer Cases in the U.S. (in Thousands), 2018-2022
Figure 81: Canada Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 82: Latin America Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 83: Latin America: Market Dynamics
Figure 84: Market Share of Latin America Lung Cancer Genomic Testing Market Revenue (by Country),
$Million, 2020 and 2031
Figure 85: Brazil Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 86: Mexico Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 87: Rest-of-Latin America (RoLA) Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 88: Market Share of Europe Lung Cancer Genomic Testing Market Revenue (by Country),
$Million, 2020 and 2031
Figure 89: Europe: Market Dynamics
Figure 90: Europe: Key Trends
Figure 91: U.K. Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 92: Germany: Lung Cancer Genomic Testing Market, $Million, 2020-2031
19. 19
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
Figure 93: Italy Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 94: Spain Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 95: France Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 96: Rest-of-Europe Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 97: Asia-Pacific Lung Cancer Genomic Testing Market (by Country), $Million, 2020 and 2031
Figure 98: Japan Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 99: China Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 100: South-Korea Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 101: Singapore Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 102: Australia Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 103: India Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 104: Rest-of-Asia-Pacific Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 105: Rest-of-the-World Lung Cancer Genomic Testing Market, $Million, 2020-2031
Figure 106: Total Number of Companies Profiled
Figure 107: QIAGEN N.V.: Product Portfolio
Figure 108: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 109: QIAGEN N.V.: Revenue (by Business Segment), 2018-2020
Figure 110: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 111: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 112: QIAGEN N.V.: SWOT Analysis
Figure 113: Agilent Technologies, Inc.: Product Portfolio
Figure 114: Agilent Technologies, Inc.: Overall Financials, 2018-2021
Figure 115: Agilent Technologies, Inc.: Revenue (by Business Segment), 2018–2021
Figure 116: Agilent Technologies, Inc.: Revenue (by Product Type), 2018–2021
Figure 117: Agilent Technologies, Inc.: Revenue (by Region), 2019-2021
Figure 118: Agilent Technologies, Inc.: R&D Expenditure, 2018-2021
Figure 119: Agilent Technologies, Inc.: SWOT Analysis
Figure 120: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 121: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2021
Figure 122: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2018–2020
Figure 123: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2018–2020
Figure 124: Thermo Fisher Scientific, Inc.: R&D Expenditure, 2018-2020
Figure 125: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 126: Quest Diagnostics Incorporated.: Product Portfolio
20. 20
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
Figure 127: Quest Diagnostics: Overall Financials, 2018-2021
Figure 128: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2018–2021
Figure 129: Quest Diagnostics Incorporated: SWOT Analysis
Figure 130: Laboratory Corporation of America Holdings: Product Portfolio
Figure 131: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 132: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 133: Laboratory Corporation of America Holdings: Revenue (by Region), 2018-2020
Figure 134: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 135: CENTOGENE N.V.: Product Portfolio
Figure 136: CENTOGENE N.V.: Overall Financials, 2018-2020
Figure 137: CENTOGENE N.V.: Revenue (by Business Segment), 2018–2020
Figure 138: CENTOGENE N.V.: Revenue (by Region), 2018-2020
Figure 139: CENTOGENE N.V.: R&D Expenditure, 2018-2020
Figure 140: CENTOGENE N.V.: SWOT Analysis
Figure 141: BGI: Product Portfolio
Figure 142: BGI: SWOT Analysis
Figure 143: CeGaT GmbH: Product Portfolio
Figure 144: CeGaT GmbH: SWOT Analysis
Figure 145: Illumina, Inc.: Product Portfolio
Figure 146: Illumina, Inc.: Overall Financials, 2018-2021
Figure 147: Illumina, Inc.: Revenue (by Business Segment), 2018–2020
Figure 148: Illumina, Inc.: Revenue (by Business Segment, by Technology), 2018–2020
Figure 149: Illumina, Inc.: Revenue (by Region), 2018–2020
Figure 150: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 151: Illumina, Inc.: SWOT Analysis
Figure 152: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 153: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2021
Figure 154: F. Hoffmann-La Roche Ltd.: Revenue (by Business Segment), 2018–2021
Figure 155: Hoffmann-La Roche Ltd.: Revenue (by Region), 2018–2020
Figure 156: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
Figure 157: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 158: Abbott Laboratories: Product Portfolio
Figure 159: Abbott Laboratories: Overall Financials, 2018-2020
Figure 160: Abbott Laboratories: Revenue (by Segment), 2018-2021
21. 21
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
Figure 161: Abbott Laboratories: Revenue (by Region), 2018-2020
Figure 162: Abbott Laboratories: R&D Expenditure, 2018-2020
Figure 163: Abbott Laboratories: SWOT Analysis
Figure 164: CD Genomics: Product Portfolio
Figure 165: CD Genomics: SWOT Analysis
Figure 166: NeoGenomics Laboratories: Product Portfolio
Figure 167: NeoGenomics Laboratories: Overall Financials, 2018-2021
Figure 168: NeoGenomics Laboratories: Revenue (by Business Segment), 2018–2021
Figure 169: NeoGenomics Laboratories: R&D Expenditure, 2018-2021
Figure 170: NeoGenomics Laboratories: SWOT Analysis
Figure 171: Admera Health: Product Portfolio
Figure 172: Admera Health: SWOT Analysis
Figure 173: OncoDNA: Product Portfolio
Figure 174: OncoDNA: SWOT Analysis
Figure 175: OPKO Health, Inc.: Product Portfolio
Figure 176: OPKO Health, Inc.: Overall Financials, 2018-2021
Figure 177: OPKO Health, Inc.: Revenue (by Region), 2018-2020
Figure 178: OPKO Health, Inc.: Revenue (by Business Segment), 2018–2021
Figure 179: OPKO Health, Inc.: R&D Expenditure, 2018-2021
Figure 180: OPKO Health, Inc.: SWOT Analysis
Figure 181: Invitae Corporation: Product Portfolio
Figure 182: Invitae Corporation: Overall Financials, 2018-2021
Figure 183: Invitae Corporation: Revenue (by Business Segment), 2018–2021
Figure 184: Invitae Corporation: R&D Expenditure, 2018-2021
Figure 185: Invitae Corporation: SWOT Analysis
Figure 186: Veracyte, Inc.: Product Portfolio
Figure 187: Veracyte, Inc.: Overall Financials, 2018-2021, $Million
Figure 188: Veracyte, Inc.: Revenue (by Business Segment), 2018–2021
Figure 189: Veracyte, Inc.: Revenue (by Region), 2018-2021
Figure 190: Veracyte, Inc.: R&D Expenditure, 2018-2021
Figure 191: Veracyte, Inc.: SWOT Analysis
22. 22
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
List of Tables
Table 1: Priority Genetic Testing at Diagnosis for Advanced Non-Squamous Non-Small Cell Lung
Cancer
Table 2: Classification of Medical Device
Table 3: Lung Cancer Genetic Mutation and Targeted Therapies
Table 4: Companies Providing Kits and Assays
Table 5: Companies Offering Services
Table 6: FDA Approved Lung Cancer NGS Assays
Table 7: Lung Cancer Insights in 2018
Table 8: Hoffmann-La Roche Ltd.: Revenue for Tissue Diagnostics Segment
23. 23
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive
in today’s digital age. We have the vision to be a leading and preferred knowledge partner for
corporates and institutions worldwide and assist them with market intelligence in the area of
emerging technologies, advisories, and other innovative solutions.
Know More Know More
Know More
Know More
24. 24
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135
25. 25
All rights reserved at BIS Research Inc.
L
u
n
g
C
a
n
c
e
r
G
e
n
o
m
i
c
T
e
s
t
i
n
g
M
a
r
k
e
t
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com